Results for 'sequencing'
iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care
From biomarker-driven breakthroughs to AI-powered early detection and a renewed commitment to equity and patient centricity, the past 12 months have seen major strides across cancer research, treatment, and communication. At Inizio, we’ve had a front-row seat to this transformation, supporting…
May 16th • 5 mins read
A. Haslam, M.S. Kim, V. Prasad
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
genome-targeted therapy, eligibility, response
Recent studies have been conducted to update the estimates of eligibility and response rates to genome-targeted therapies among US cancer patients, reflecting data up to 2020. The number of FDA-approved drugs targeting genetic indications has increased significantly since prior assessments. …
Apr 20th • 7 mins read
Pai, Rekha
Advances in basic research in oncology in 2020: Bridging basic science and clinical care
advances, research, oncology, PCAWG, 2020
Cancer research is advancing with an understanding of the disease at the genetic level, facilitated by massive parallel sequencing. The pan-cancer analysis of the whole genome (PCAWG) in 2020 documented genomic changes across 38 cancer types, involving 2658 cancer genomes. An average of four to …
Mar 24th • 1 min read
Ali Raza Khaki
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
precision oncology, TMB-high, homologous recombination deficiency, Olaparib, pembrolizumab
Precision oncology aims to tailor cancer treatment based on genetic understanding, revolutionizing oncology. The FDA has been approving drugs under precision oncology with broad indications that may not align with studied populations. Examples include the approval of pembrolizumab for a wide ran…
Dec 1st • 4 mins read
Carrie Printz
First person profile: William Sellers, MD
William Sellers, Dana Farber Cancer Institute, Harvard, melanoma
Dr. Sellers is a prominent figure in cancer research, associated with the Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, and Harvard Medical School. He has contributed significantly to cancer genomics, particularly in identifying EGFR mutations in lung cancer a…
Nov 6th • 2 mins read
Dean Bottino, Rachael Liu, Hojjat Bazzazi, Karthik Venkatakrishnan
Quantitative Translation in Immuno-Oncology Research and Development
Quantitative Translation, Immuno-Oncology, Research, Development, CIC
Exploring the therapeutic potential of the rapidly expanding field of immuno-oncology (IO) drug targets and diverse therapeutic modalities. Recognizing the need for principled decisions based on biologically sound quantitative translation in a competitive clinical research environment. High…
Jul 9th • 3 mins read
Fernando Petracci, Chirag Ghai, Andrew Pangilinan, Luis Alberto Suarez, Roberto Uehara, Marwan Ghosn
Use of real-world evidence for oncology clinical decision making in emerging economies
Asia-Pacific, effectiveness, electronic database, health policy, Latin America, Middle East, randomized clinical trials, real-world data, real-world evidence, safety
Despite RWE being a relatively nascent concept in emerging economies, we have seen evidence of increasing use over the past 5 years growing at 11% per year. That said, barriers specific to emerging economies need to be overcome through collaborative efforts, with regulatory agencies at the forefront…
May 5th • 12 mins read
Ajaikumar B Kunnumakkara kunnumakkara@iitg.ac.in, Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Nand Kishor Roy, Krishan Kumar Thakur, Kishore Banik, Mehdi Shakibaei, Subash C Gupta, and Bharat B Aggarwal
Cancer drug development: The missing links
Cancer, drugs, patient survival, pre-clinical, clinical, cost
Despite advanced science and technology, cancer incidence is highest in America and Europe. Science and technology alone are not sufficient for treating diseases like cancer. Over 95% of drugs/compounds that show promise in pre-clinical trials fail in phase I clinical trials in humans. Most pre…
Apr 18th • 20 mins read